TNFRSF12A and glioblastoma: In summary, the here presented data show for the first time that not only T cells, but also NK-92 cells can be modified with RevCARs and that the resulting RevCAR-expressing immune cells can be used for targeting of Fn14-positive GBM cells using the novel anti-Fn14 RevTMs with high target-specificity and tumor killing efficiency.